Company intelligence / Profile preview

ResoTher Pharma

Ownership: Private
Development stage: Other

Overview

ResoTher Pharma has initiated dosing in its Phase 2a clinical trial evaluating RTP026, an Annexin A1-derived peptide therapeutic, in patients with myocardial infarction. Preclinical data show that RTP026 regulates immune cell recruitment and promotes tissue repair by mimicking endogenous resolution of inflammation. The company’s approach addresses unmet needs in cardiovascular care by targeting the inflammatory component not addressed by current therapies.

Therapeutic areas: ImmunologyCardiovascular
Modalities: PeptidesRecombinant peptide
Industry: Biotech

Drug pipeline

2 assets

RTP-026

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharma partnerships publicly disclosed; received grant funding from European Innovation Council and Nordic Mentor Network of Entrepreneurship.

Beyond the preview

Go deeper on ResoTher Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ResoTher Pharma.

Explore the full profile